Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usnoflast (ZYIL1) in mild to moderate ulcerative colitis
NCT06398808Phase 2Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of usnoflast in ulcerative colitis (UC) (2 arms), sponsored by Zydus Lifesciences Limited. Primary endpoint: Induction of clinical remission at Week 6. Started Apr 2024; status: completed.
02
Drugs
usnoflast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06398808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398808.